Sarepta Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.11.24	Sarepta Therapeutics Q3 Earnings Summary (RTTNews)
07.08.24	Sarepta Therapeutics Q2 Earnings Summary (RTTNews)
21.06.24	Sarepta Therapeutics' Elevidys Approved By FDA For Duchenne Muscular Dystrophy; Stock Surges (RTTNews)
01.05.24	Sarepta Therapeutics Q1 Earnings Summary (RTTNews)
28.02.24	Sarepta Therapeutics Q4 Earnings Summary (RTTNews)
16.02.24	Sarepta Says FDA Accepted Efficacy Supplement To BLA For Elevidys (RTTNews)
29.01.24	Sarepta Reports Positive Data From MOMENTUM Study Of SRP-5051 In Duchenne Muscular Dystrophy (RTTNews)
05.11.23	ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT (PR Newswire)
01.11.23	Sarepta Therapeutics Q3 Earnings Summary (RTTNews)
30.08.23	Quest Diagnostics Says FDA Grants Breakthrough Designation For Adeno-associated Virus Test (RTTNews)
02.08.23	Sarepta Therapeutics Q2 Loss Decreases, beats estimates (RTTNews)
23.06.23	FDA OKs Elevidys As First Gene Therapy To Treat Duchenne Muscular Dystrophy (RTTNews)
24.05.23	Sarepta Therapeutics Updates Of BLA For Sarepta's Duchenne Muscular Dystrophy Drug Candidate (RTTNews)
02.05.23	Sarepta Therapeutics Q1 Loss Increases, but beats estimates (RTTNews)
14.04.23	ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT (PR Newswire)
06.04.23	SRPT LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT (PR Newswire)
25.03.23	SRPT INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT (PR Newswire)
20.03.23	INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT (PR Newswire)
17.03.23	Pre-market Movers: ENZ, HUBC, SRPT, MNPR, THMO… (RTTNews)
01.03.23	Pre-market Movers: RETA, ONCS, LION, NVAX, SRPT… (RTTNews)
28.02.23	Sarepta Therapeutics Q4 Loss Decreases, beats estimates (RTTNews)
28.11.22	Sarepta: FDA To Review BLA For SRP-9001 - Quick Facts (RTTNews)
02.11.22	Sarepta Therapeutics Q3 Loss increases, misses estimates (RTTNews)
29.09.22	Sarepta Submits BLA For SRP-9001 To Treat Ambulant Patients With Duchenne Muscular Dystrophy (RTTNews)
14.09.22	Sarepta Therapeutics Prices $1 Bln Convertible Senior Notes (RTTNews)
06.09.22	Sarepta Therapeutics Says FDA Lifts Clinical Hold On SRP-5051 To Treat Duchenne Muscular Dystrophy (RTTNews)
05.05.22	Pre-market Movers: AUST, HYMC, BLUE, CASA, AMWL… (RTTNews)
04.05.22	Sarepta Therapeutics Q1 Loss Increases, but beats estimates (RTTNews)
01.03.22	Sarepta Therapeutics Q4 Loss Increases, but beats estimates (RTTNews)
04.08.21	Sarepta Therapeutics Q2 adjusted earnings Miss Estimates (RTTNews)
18.05.21	Stock Alert: Sarepta Therapeutics Up 9% (RTTNews)
18.05.21	Sarepta's Gene Therapy For Treatment Of Duchenne Muscular Dystrophy Shows Robust Expression (RTTNews)
05.05.21	Sarepta Therapeutics Q1 adjusted earnings Beat Estimates (RTTNews)
01.03.21	Sarepta Therapeutics Q4 adjusted earnings Miss Estimates (RTTNews)
08.01.21	Pre-market Movers In Healthcare Sector: MRUS, OGEN, JAGX, CVAC, SRPT… (RTTNews)
08.01.21	ALDX Catches Eye, RVNC Faces Busy Year Ahead, SRPT Plunges On DMD Trial Data (RTTNews)
26.08.20	CYCN To Report IW-6463 Data In Sep, IMVT Hits New High, SRPT On Watch, MDWD Keeps Word To BARDA (RTTNews)
11.08.20	Sarepta, University Of Florida To Accelerate Development Of Therapies For Rare Genetic Diseases (RTTNews)
19.06.20	FDA Nod For EPZM, RARE, Court Rules In MYL's Favor, Ocuphire To Hop Onto Nasdaq, ALPN Soars (RTTNews)
09.06.20	SLNO Fails To Whet Investors' Appetite, OPNT And EBS Slump On Court Ruling, ENOB On Track (RTTNews)
07.05.20	Sarepta Therapeutics Q1 adjusted earnings Beat Estimates (RTTNews)
24.12.19	ACST On Watch, ITCI Jumps 250% On Trial Data, CVM Slumps, FDA Nod For AGN (RTTNews)
13.12.19	First Generic Version Of NuvaRing Gets FDA Nod, ONCT On Watch, SRPT Surges (RTTNews)
07.11.19	Sarepta Therapeutics Q3 adjusted earnings Beat Estimates (RTTNews)
21.08.19	5 Top Losers In Healthcare Sector (SYBX, PSTV, TRIB…) (RTTNews)
19.08.19	VNDA - Lag Or Rise? ANAB - Gallop Or Flounder? And More... (RTTNews)
07.08.19	Sarepta Therapeutics Q2 adjusted earnings Beat Estimates (RTTNews)
29.07.19	Biotech Stocks Facing FDA Decision In August 2019 (RTTNews)
27.02.19	Sarepta Therapeutics Q4 adjusted earnings Beat Estimates (RTTNews)
27.02.19	Sarepta Therapeutics Acquires Myonexus Therapeutics For $165 Million (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Sarepta Therapeutics Inc.

Aktien Top/Flop

Sarepta Therapeutics Peer Group Nachrichten

Meistgelesene Nachrichten